VRCA (Verrica Pharmaceuticals) Accounts Payable: $1.60 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRCA Verrica Pharmaceuticals Inc VRCA
45 GF Score
Price $4.99
GF Value $13.24
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Verrica Pharmaceuticals Accounts Payable?

Verrica Pharmaceuticals VRCA -7.25% 45 Accounts Payable is $1.60 Mil as of Jun. 2026. GuruFocus rates VRCA with a GF Score™ of 45/100 and a GF Value™ of $13.24 (Possible Value Trap). The stock has 2 warning signs investors should review.

Verrica Pharmaceuticals's Accounts Payable for the quarter that ended in Jun. 2026 was $1.60 Mil.

Verrica Pharmaceuticals's quarterly Accounts Payable increased from Dec. 2025 ($2.07 Mil) to Mar. 2026 ($2.19 Mil) but then declined from Mar. 2026 ($2.19 Mil) to Jun. 2026 ($1.60 Mil).

Verrica Pharmaceuticals's annual Accounts Payable declined from Dec. 2023 ($2.46 Mil) to Dec. 2024 ($1.90 Mil) but then increased from Dec. 2024 ($1.90 Mil) to Dec. 2025 ($2.07 Mil).

Verrica Pharmaceuticals Accounts Payable Related Terms

Verrica Pharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for Verrica Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Verrica Pharmaceuticals Accounts Payable Chart

Verrica Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.85 0.51 2.46 1.90 2.07

Verrica Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.32 1.59 2.07 2.19 1.60
VRCA
45GF Score
Verrica Pharmaceuticals Inc VRCA
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Verrica Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $1.60 Mil mean?
Verrica Pharmaceuticals (VRCA) has a Accounts Payable of $1.60 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Verrica Pharmaceuticals and its competitors.
Is Verrica Pharmaceuticals' Accounts Payable too high?
Verrica Pharmaceuticals' current Accounts Payable is $1.60 Mil. Overall, Verrica Pharmaceuticals has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Verrica Pharmaceuticals' Accounts Payable compare to HRTX and RLYB?
Verrica Pharmaceuticals' Accounts Payable of $1.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Verrica Pharmaceuticals and its competitors. Verrica Pharmaceuticals's current Accounts Payable is $1.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verrica Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Verrica Pharmaceuticals (VRCA) is currently considered Possible Value Trap. The stock's GF Value™ is $13.24, compared to a current price of $4.99 — trading 62.3% below its estimated fair value. The current Accounts Payable is $1.60 Mil. Verrica Pharmaceuticals' overall GF Score™ is 45/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Verrica Pharmaceuticals (VRCA), the current Accounts Payable is $1.60 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Verrica Pharmaceuticals (VRCA) Overvalued in 2026?

Based on GuruFocus' analysis, Verrica Pharmaceuticals stock appears to be undervalued. The current stock price of $4.99 is trading 62.3% below its estimated GF Value™ of $13.24. GuruFocus considers Verrica Pharmaceuticals to be Possible Value Trap.

Key valuation signals for VRCA:

  • Accounts Payable: $1.60 Mil
  • GF Value™: $13.24 vs. price of $4.99 (62.3% below fair value)
  • GF Score™: 45/100 with 2 warning signs

No single metric tells the full story. See the VRCA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Verrica Pharmaceuticals Business Description

Other Exchanges 1NE0:Germany
Address 44 West Gay Street, Suite 400, West Chester, PA, USA, 19380
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
45GF Score

Get the complete analysis for VRCA

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.99
Price
$13.24
GF Value